A glycoproteomic approach to identify novel glycomarkers for cancer stem cells

Proteomics

Volumn 16, Issue 24, 2016, Pages 3073-3080

  Sawanobori, Atsuko ^a   Moriwaki, Kenta ^a   Takamatsu, Shinji ^a   Kamada, Yoshihiro ^a   Miyoshi, Eiji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer stem cells; Fucosylation; Glycoproteomics; Hepatic progenitor cells; Lectin; Sialylation

Indexed keywords

BIOLOGICAL MARKER; GLYCAN; GLYCOPROTEIN; LECTIN; SAMBUCUS SIEBOLDIANA AGGLUTININ; UNCLASSIFIED DRUG; FUCOSE; N ACETYLNEURAMINIC ACID; POLYSACCHARIDE; PROTEOME; TUMOR MARKER;

CANCER STEM CELL; CELL ISOLATION; FUCOSYLATION; HEPATIC PROGENITOR CELL; LIVER CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIALYLATION; ANIMAL; CELL SEPARATION; CHEMISTRY; HUMAN; NEOPLASM; PATHOLOGY; PROCEDURES; PROTEOMICS;

ANIMALS; BIOMARKERS, TUMOR; CELL SEPARATION; FUCOSE; GLYCOPROTEINS; HUMANS; N-ACETYLNEURAMINIC ACID; NEOPLASMS; NEOPLASTIC STEM CELLS; POLYSACCHARIDES; PROTEOME; PROTEOMICS;

EID: 84966588555     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201500472     Document Type: Review

References (62)

1. Ailles, L. E., Weissman, I. L., Cancer stem cells in solid tumors. Curr. Opin. Biotechnol. 2007, 18, 460–466.
2. Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J. et al., Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66, 9339–9344.
3. Dean, M., Fojo, T., Bates, S., Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5, 275–284.
4. Pinho, S. S., Reis, C. A., Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer 2015, 15, 540–555.
5. Ohtsubo, K., Marth, J. D., Glycosylation in cellular mechanisms of health and disease. Cell 2006, 126, 855–867.
6. Dennis, J. W., Laferte, S., Waghorne, C., Breitman, M. L., Kerbel, R. S., Beta 1–6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 1987, 236, 582–585.
7. Taniguchi, N., Miyoshi, E., Ko, J. H., Ikeda, Y., Ihara, Y., Implication of N-acetylglucosaminyltransferases III and V in cancer: gene regulation and signaling mechanism. Biochim. Biophys. Acta 1999, 1455, 287–300.
8. Chandler, K., Goldman, R., Glycoprotein disease markers and single protein-omics. Mol. Cell. Proteomics 2013, 12, 836–845.
9. Muramatsu, T., Muramatsu, H., Carbohydrate antigens expressed on stem cells and early embryonic cells. Glycoconj. J. 2004, 21, 41–45.
10. Martin, M. J., Muotri, A., Gage, F., Varki, A., Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat. Med. 2005, 11, 228–232.
11. Duncan, A. W., Dorrell, C., Grompe, M., Stem cells and liver regeneration. Gastroenterology 2009, 137, 466–481.
12. McMahon, J. B., Richards, W. L., del Campo, A. A., Song, M. K., Thorgeirsson, S. S., Differential effects of transforming growth factor-beta on proliferation of normal and malignant rat liver epithelial cells in culture. Cancer Res. 1986, 46, 4665–4671.
13. Bisgaard, H. C., Nagy, P., Ton, P. T., Hu, Z., Thorgeirsson, S. S., Modulation of keratin 14 and alpha-fetoprotein expression during hepatic oval cell proliferation and liver regeneration. J. Cell. Physiol. 1994, 159, 475–484.
14. Sanchez, A., Factor, V. M., Espinoza, L. A., Schroeder, I. S., Thorgeirsson, S. S., In vitro differentiation of rat liver derived stem cells results in sensitization to TNFalpha-mediated apoptosis. Hepatology 2004, 40, 590–599.
15. Sasaki, N., Moriwaki, K., Uozumi, N., Noda, K. et al., High levels of E4-PHA-reactive oligosaccharides: potential as marker for cells with characteristics of hepatic progenitor cells. Glycoconj. J. 2009, 26, 1213–1223.
16. Kuno, A., Uchiyama, N., Koseki-Kuno, S., Ebe, Y. et al., Evanescent-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling. Nat. Methods 2005, 2, 851–856.
17. Yamashita, K., Hitoi, A., Kobata, A., Structural determinants of Phaseolus vulgaris erythroagglutinating lectin for oligosaccharides. J. Biol. Chem. 1983, 258, 14753–14755.
18. Terada, K., Sugiyama, T., The Long-Evans Cinnamon rat: an animal model for Wilson's disease. Pediatr. Int. 1999, 41, 414–418.
19. Yasui, O., Miura, N., Terada, K., Kawarada, Y. et al., Isolation of oval cells from Long-Evans Cinnamon rats and their transformation into hepatocytes in vivo in the rat liver. Hepatology 1997, 25, 329–334.
20. Visvader, J. E., Lindeman, G. J., Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8, 755–768.
21. Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A. et al., Identification of human brain tumour initiating cells. Nature 2004, 432, 396–401.
22. O'Brien, C. A., Pollett, A., Gallinger, S., Dick, J. E., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445, 106–110.
23. Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M. et al., Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445, 111–115.
24. Yin, S., Li, J., Hu, C., Chen, X. et al., CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 2007, 120, 1444–1450.
25. Haraguchi, N., Ohkuma, M., Sakashita, H., Matsuzaki, S. et al., CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann. Surg. Oncol. 2008, 15, 2927–2933.
26. Haraguchi, N., Ishii, H., Mimori, K., Tanaka, F. et al., CD13 is a therapeutic target in human liver cancer stem cells. J. Clin. Invest. 2010, 120, 3326–3339.
27. Moriwaki, K., Okudo, K., Haraguchi, N., Takeishi, S. et al., Combination use of anti-CD133 antibody and SSA lectin can effectively enrich cells with high tumorigenicity. Cancer Sci. 2011, 102, 1164–1170.
28. Ito, H., Kuno, A., Sawaki, H., Sogabe, M. et al., Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools. J. Proteome Res. 2009, 8, 1358–1367.
29. Yamashita, T., Ji, J., Budhu, A., Forgues, M. et al., EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136, 1012–1024.
30. Zhu, Z., Hao, X., Yan, M., Yao, M. et al., Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int. J. Cancer 2010, 126, 2067–2078.
31. Chiba, T., Miyagi, S., Saraya, A., Aoki, R. et al., The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res. 2008, 68, 7742–7749.
32. Ikehara, Y., Kojima, N., Kurosawa, N., Kudo, T. et al., Cloning and expression of a human gene encoding an N-acetylgalactosamine-alpha2,6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-associated sialyl-Tn antigens. Glycobiology 1999, 9, 1213–1224.
33. Kobayashi, H., Terao, T., Kawashima, Y., Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J. Clin. Oncol. 1992, 10, 95–101.
34. Nakagoe, T., Sawai, T., Tsuji, T., Jibiki, M. et al., Pre-operative serum levels of sialyl Tn antigen predict liver metastasis and poor prognosis in patients with gastric cancer. Eur. J. Surg. Oncol. 2001, 27, 731–739.
35. Ferreira, J. A., Videira, P. A., Lima, L., Pereira, S. et al., Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours. Mol. Oncol. 2013, 7, 719–731.
36. Munkley, J., Oltean, S., Vodak, D., Wilson, B. T. et al., The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget 2015, 6, 34358–34374.
37. Julien, S., Adriaenssens, E., Ottenberg, K., Furlan, A. et al., ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology 2006, 16, 54–64.
38. Ozaki, H., Matsuzaki, H., Ando, H., Kaji, H. et al., Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clin. Exp. Metastasis 2012, 29, 229–238.
39. Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A. et al., Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1, 313–323.
40. Azuma, K., Serada, S., Takamatsu, S., Terao, N. et al., Identification of sialylated glycoproteins in Doxorubicin-treated hepatoma cells with glycoproteomic analyses. J. Proteome Res. 2014, 13, 4869–4877.
41. Zieske, L. R., A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J. Exp. Bot. 2006, 57, 1501–1508.
42. Ohnishi, T., Nakamura, O., Ozawa, M., Arakaki, N. et al., Molecular cloning and sequence analysis of cDNA for a 59 kD bone sialoprotein of the rat: demonstration that it is a counterpart of human alpha 2-HS glycoprotein and bovine fetuin. J. Bone Miner. Res. 1993, 8, 367–377.
43. Sato, M., Kamada, Y., Takeda, Y., Kida, S. et al., Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int. 2015, 35, 925–935.
44. Terao, N., Takamatsu, S., Minehira, T., Sobajima, T. et al., Fucosylation is a common glycosylation type in pancreatic cancer stem cell-like phenotypes. World J. Gastroenterol. 2015, 21, 3876–3887.
45. Li, C., Heidt, D. G., Dalerba, P., Burant, C. F. et al., Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67, 1030–1037.
46. Miyoshi, E., Moriwaki, K., Nakagawa, T., Biological function of fucosylation in cancer biology. J. Biochem. 2008, 143, 725–729.
47. Narisada, M., Kawamoto, S., Kuwamoto, K., Moriwaki, K. et al., Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem. Biophys. Res. Commun. 2008, 377, 792–796.
48. Zhang, Y., Yan, W., Collins, M. A., Bednar, F. et al., Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 2013, 73, 6359–6374.
49. Bull, C., Stoel, M. A., den Brok, M. H., Adema, G. J., Sialic acids sweeten a tumor's life. Cancer Res. 2014, 74, 3199–3204.
50. Yogeeswaran, G., Salk, P. L., Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science 1981, 212, 1514–1516.
51. Zhou, B. B., Zhang, H., Damelin, M., Geles, K. G. et al., Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8, 806–823.
52. Yamashita, T., Wang, X. W., Cancer stem cells in the development of liver cancer. J. Clin. Invest. 2013, 123, 1911–1918.
53. Cabrera, M. C., Hollingsworth, R. E., Hurt, E. M., Cancer stem cell plasticity and tumor hierarchy. World J. Stem Cells 2015, 7, 27–36.
54. Aoyagi, Y., Suzuki, Y., Isemura, M., Nomoto, M. et al., The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 1988, 61, 769–774.
55. Okuyama, N., Ide, Y., Nakano, M., Nakagawa, T. et al., Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int. J. Cancer 2006, 118, 2803–2808.
56. Takeda, Y., Shinzaki, S., Okudo, K., Moriwaki, K. et al., Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer. Cancer 2012, 118, 3036–3043.
57. Fujita, K., Shimomura, M., Uemura, M., Nakata, W. et al., Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer. Prostate 2014, 74, 1052–1058.
58. Asazawa, H., Kamada, Y., Takeda, Y., Takamatsu, S. et al., Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development. Clin. Chem. Lab. Med. 2015, 53, 95–102.
59. Jin, L., McLean, P. A., Neel, B. G., Wortis, H. H., Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling. J. Exp. Med. 2002, 195, 1199–1205.
60. Liu, Y. C., Yen, H. Y., Chen, C. Y., Chen, C. H. et al., Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc. Natl. Acad. Sci. U S A 2011, 108, 11332–11337.
61. Wang, X., Inoue, S., Gu, J., Miyoshi, E. et al., Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc. Natl. Acad. Sci. U S A 2005, 102, 15791–15796.
62. Zhao, Y., Itoh, S., Wang, X., Isaji, T. et al., Deletion of core fucosylation on alpha3beta1 integrin down-regulates its functions. J. Biol. Chem. 2006, 281, 38343–38350.